BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

IL-7: Interim Phase I data

Interim data from an ongoing, open-label, U.S. Phase I trial in 8 evaluable patients showed that weekly subcutaneous injections of 10 or 20 µg/kg CYT107 for 3 weeks led to a median increase in CD4+ T cells exhibiting a naïve or central memory phenotype of 69%...

Read the full 209 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >